Description
Sangivamycin is a nucleoside analog.1 It incorporates into severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and reduces the number of plaque-forming units (PFUs) in SARS-CoV-2-infected Vero E6 cells when used at a concentration of 72 nM. Sangivamycin (0.3 µM) induces cell cycle arrest at the G2/M phase and apoptosis in MCF-7/adr cells, effects that can be prevented by the JNK inhibitor SP600125 (Item No. 10010466) or protein kinase Cδ (PKCδ) inhibitor rottlerin (Item No. 12006).2WARNING This product is not for human or veterinary use.
References
[1] RYAN P. BENNETT . Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase[J]. Antiviral research, 2023, 218: Article 105716. DOI:
10.1016/j.antiviral.2023.105716[2] SUNG A LEE Mira J. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation.[J]. The Journal of Biological Chemistry, 2007: 15271-15283. DOI:
10.1074/jbc.m701362200
